PhuturdexDrug Pipeline Intelligence

Phuturdex › Diseases › Hereditary angioedema

Drugs in development · updated 30 October 2026

Hereditary angioedema: drugs in development

Rare diseasePrevalence 1-9 / 100 000 according to Orphanet · ORPHA:91378

As of 30 October 2026 there are 18 active clinical trials (recruiting or ongoing, phases I–III) on 8 drugs for hereditary angioedema. 6 are experimental, that is not yet approved in the United States.

18Active trials
6Experimental drugs
4Experimental, in phase III

Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.

Sign in free →

Experimental drugs

Not yet approved by the US FDA for any indication.

DrugMost advanced phaseActive trialsReference trial
DeucrictibantII–III5NCT05396105
ADX-324III3NCT06960213
NavenibartSTAR-0215III3NCT07204938
NTLA-2002III1NCT06634420
BerinertII1NCT06919003
BW-20805II1NCT06846398

Sorted by most advanced phase and number of active trials.

Approved drugs in new trials

Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.

DrugMost advanced phaseActive trialsReference trial
BerotralstatOrladeyo®III2NCT05453968
DonidalorsenDawnzera (Autoinjector)®, Dawnzera®III2NCT07298447

Sorted by most advanced phase and number of active trials.

All 8 drugs, with the details

In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.

Open in Phuturdex →

Broader categories

Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D054179 “Angioedemas, Hereditary”. Prevalence: Orphanet.

ItalianoFrançaisDeutsch